ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0716

Utility of Follow-Up Cardiac Magnetic Resonance Imaging In Patients With Eosinophilic Granulomatosis With Polyangiitis

Chelsea Cheng1, Justine Lafleur-Careau2, Navneet Kang1, Medha Soowamber3 and Christian Pagnoux3, 1Mount Sinai Hospital, Toronto, Canada, 2Mount Sinai Hospital, Saint-Augustin-de-Desmaures, Canada, 3Mount Sinai Hospital, Toronto, ON, Canada

Meeting: ACR Convergence 2025

Keywords: ANCA associated vasculitis, Eosinophilic Granulomatosus with Polyangiitis (Churg-Strauss), Magnetic resonance imaging (MRI)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 26, 2025

Title: (0711–0730) Vasculitis – ANCA-Associated Poster I

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare multisystem disorder characterized by asthma, rhinitis, peripheral blood eosinophilia, and necrotizing vasculitis of small vessels. Cardiac involvement occurs in approximately 10-30% of patients with EGPA and has been identified as a major predictor of mortality. Cardiac manifestations can be diagnosed clinically, as well as through electrocardiogram and echocardiogram. Cardiac magnetic resonance (CMRI) has higher sensitivity to detect cardiac involvement, especially late gadolinium enhancement (LGE), which can indicate myocardial inflammation and/or fibrosis. However, the exact role of CMRI at diagnosis and the utility of repeat CMRI to monitor evolution of cardiac manifestations in EGPA remain unclear. Our aim was to report on the use and findings of CMRI in our EGPA patient cohort, determine the added value of repeat CMRI, and evaluate the outcome and prognostic value of persistent LGE.

Methods: In this monocentric retrospective descriptive cohort study, we included 75 patients diagnosed with EGPA who were seen at least twice between 2015 and January 2023, of which 30 patients had undergone CMRI, with 11 patients undergoing repeat CMRI during follow-up. All patients satisfied the 2022 ACR/EULAR Classification Criteria for EGPA.

Results: 75 patients (male 56%, mean age at diagnosis 46 years, 2022 ACR/EULAR score range 6-13) seen at least twice in the clinic between 2015 and January 2023 were included. Antineutrophil cytoplasmic antibody (ANCA) was positive in 29 patients (39%), with 22 (39%) being anti-myeloperoxidase antibody (anti-MPO) positive and 4 (5%) being perinuclear ANCA (p-ANCA) positive. 17 (23%) had cardiac symptoms, such as chest pain, orthopnea, and syncope. 30 patients underwent CMRI, 9 (30%) of whom had cardiac symptoms. 11 underwent one or more repeat CMRI. All 30 patients (100%) were treated with glucocorticoids, with 13 (43%) also receiving cyclophosphamide. 11/11 patients who underwent repeat CMRI had LGE on first CMRI, 10/11 had persistent LGE on second CMRI, 4/4 had LGE on third CMRI, and 2/2 had LGE on fourth CMRI. The average time between first CMRI and second CMRI was 22 months (range 4-81 months). Of the 30 patients, 3 (10%) had cardiovascular events at follow-up, 2 of whom had atrial fibrillation (neither had LGE on their CMRIs), and 1 of whom had coronary artery disease requiring stenting (with LGE on his 4 CMRIs).

Conclusion: The role of initial and further serial CMRIs to study and monitor cardiac involvement in EGPA remains unclear. Late gadolinium enhancement most often persists despite treatment, with no major differences in adverse cardiac outcomes in this cohort.


Disclosures: C. Cheng: None; J. Lafleur-Careau: None; N. Kang: None; M. Soowamber: AbbVie/Abbott, 1, 6, GlaxoSmithKlein(GSK), 1, 6, Otsuka, 1, 6; C. Pagnoux: AstraZeneca, 1, ChemoCentryx, 1, GlaxoSmithKlein(GSK), 1, 5, InflaRx GmbH, 1, otsuka, 1, 5, Pfizer, 1, 5, Roche, 1, 5.

To cite this abstract in AMA style:

Cheng C, Lafleur-Careau J, Kang N, Soowamber M, Pagnoux C. Utility of Follow-Up Cardiac Magnetic Resonance Imaging In Patients With Eosinophilic Granulomatosis With Polyangiitis [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/utility-of-follow-up-cardiac-magnetic-resonance-imaging-in-patients-with-eosinophilic-granulomatosis-with-polyangiitis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/utility-of-follow-up-cardiac-magnetic-resonance-imaging-in-patients-with-eosinophilic-granulomatosis-with-polyangiitis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology